Thalidomide for the treatment of myelodysplastic syndrome in Taiwan: Results of a phase II trial

Chih Yuan Chung, Sheng Fung Lin, Po Min Chen, Ming Chih Chang, Woei You Kao, Tsu Yi Chao, Liang Tsai Hsiao, Chuen Chuan Yen, Muh Hwa Yang, Wei Shou Hwang, Tung Liang Lin, Tzeon Jye Chiou, Cheng Shyong Chang

研究成果: 雜誌貢獻文章同行評審

6 引文 斯高帕斯(Scopus)

摘要

Background: Thalidomide inhibits angiogenesis and exerts complex immunomodulatory activities. This phase II study aimed to examine the efficacy of thalidomide in Taiwanese patients with myelodysplastic syndrome (MDS). Patients and Methods: Sixty patients [intention to treat group (ITT)] with MDS were treated with thalidomide (100 mg/day, increased by 100 mg/day weekly to a maximum of 400 mg/day) for 12 weeks. Forty-two patients of the ITT group were considered as comprising the evaluable population (EP). Results: Thalidomide resulted in hematological improvement (HI) in 28% of ITT analysis and in HI in 40% of the EP. Thalidomide was more effective for MDS patients with low to intermediate-1 International Prognostic Score System scores. The response rates were 7% for ITT and 10% for EP patients. Only two patients exhibited a cytogenetic response. Net reduced levels of vascular endothelial growth factor and basic fibroblast growth factor cytokines were observed in the peripheral blood and the bone marrow of thalidomide-treated patients. Conclusion: Low-dose thalidomide is an effective and safe treatment for patients with low-risk MDS.

原文英語
頁(從 - 到)3415-3419
頁數5
期刊Anticancer Research
32
發行號8
出版狀態已發佈 - 八月 2012
對外發佈Yes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

指紋 深入研究「Thalidomide for the treatment of myelodysplastic syndrome in Taiwan: Results of a phase II trial」主題。共同形成了獨特的指紋。

引用此